WHAT IS CLAIMED IS:

1. A compound of the formula

$$U\text{-}V\text{-}A\text{-}(Alk)_j\text{-}(C(O)\text{-}NH)_h\text{-}(Alk)_g\text{-}B$$

or a pharmaceutically acceptable salt thereof, wherein g, h and j are each independently 0 or 1; provided when h is 0, then g is 0;

each Alk is independently a alkyl radical;

U represents amidino, guanidino, $-(G\text{-alkyl})_k\text{-}NH\text{-}R_1$, $-(G\text{-alkyl})_k\text{-}NH\text{-}C(Q)\text{-}R_1$, $-(G\text{-alkyl})_k\text{-}C(Q)\text{-}N(R)\text{-}R_1$, $-(G\text{-alkyl})_k\text{-}NH\text{-}C(Q)\text{-}N(R)\text{-}R_1$, $-(G\text{-alkyl})_k\text{-}NH\text{-}C(Q)\text{-}O\text{-}R_1$ or $-(G\text{-alkyl})_k\text{-}O\text{-}C(Q)\text{-}N(R)\text{-}R_1$ radical; or U represents a hydroxyalkyl-G- radical which is optionally substituted by a cycloalkyl, aryl, heteroaryl or heterocyclyl, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2;

wherein k is 0 or 1;

G represents a bond, O, S or NH;

Q represents O, S, NH, N-CN or N-alkyl;

R is a radical of hydrogen or alkyl;

R_1 is a radical of alkyl, haloalkyl, $R_{21}R_{22}N$-alkyl, $R_{21}O$-alkyl, $R_{21}S$-alkyl, cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heteroaryl, heteroaryl-alkyl, heterocyclyl or heterocyclyl-alkyl, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2;

wherein R_{21} and R_{22} are each independently a radical of hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heteroaryl, heteroaryl-alkyl, heterocyclyl or heterocyclyl-alkyl, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2;

each R_2 is independently a halo, alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, hydroxy, carboxy, cyano, azido, amidino, guanidino, nitro, amino, alkylamino or dialkylamino radical or two adjacent R_2 radicals on an aryl or heteroaryl radical represent a methylenedioxy, ethylenedioxy or propylenedioxy radical;

V represents a radical of formula







wherein W_1 is O, S or N-R_3; wherein each R_3 is independently a hydrogen or alkyl radical; W_7 is N or C-R_7; W_8 is N or C-R_5;

W_9 is $C(R_3)_2$ and W_{10} is W_1; or W_9 is CR_3R_5 and W_{10} is $C(R_3)_2$;

each W_2, W_3, W_4 and W_5 are independently N or C-R_4; provided the total number of cycloalkyl, aryl, heteroaryl, heterocyclyl, carboxy, -C(O)-O-R_{19}, -C(O)-R_{19}, -C(O)-NH-R_{19}, -C(O)-N(R_{19})$_2$ and -R_{19} radicals in W_2, W_3, W_4 and W_5 is 0-2;

each W_6 is independently N or C-H; provided that not more than two of W_2, W_3, W_4, W_5 and W_6 represent N; and

each R_4 is independently a hydrogen, halo, alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, hydroxy,

cyano, carboxy, $-C(O)-O-R_{19}$, $-C(O)-R_{19}$, $-C(O)-NH-R_{19}$, $-C(O)-N(R_{19})_2$, cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heteroaryl, heteroaryl-alkyl, heterocyclyl or heterocyclyl-alkyl radical, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2; or two adjacent R_4 radicals taken together with the carbon atoms to which they are attached represent a fused-phenyl or fused-heteroaryl of 5-6 ring members, wherein the phenyl and heteroaryl radicals are optionally substituted by 1-3 radicals of R_2;

R_5, R_6 and R_7 are each independently a hydrogen, halo, alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, hydroxy or cyano radical; or R_5 and R_6 or R_6 and R_7 taken together with the carbon atoms to which they are attached represent a fused-phenyl or fused-heteroaryl of 6 ring members, wherein the phenyl and heteroaryl radicals are optionally substituted by 1-3 radicals of R_2; or R_3 and R_6 taken together with the carbon atoms to which they are attached represent a fused-heteroaryl of 6 ring members optionally substituted by 1-3 radicals of R_2;

A represents a radical of formula


,

,

,

or

;

wherein X_1 is N or C-H;

X_2 is C-H, C-alkyl, a spirocycloalkyl or spiroheterocyclyl radical; wherein the spirocycloalkyl and spiroheterocyclyl radicals are optionally substituted by an oxo or thiooxo radical and 1-2 radicals of alkyl, haloalkyl, hydroxy, alkoxy or haloalkoxy;

Y_1 is -C(O)-, -C(S)-, -S(O)- or $-S(O)_2-$;

Z_1 is O or $N-R_{12}$;

Z_2 is O, S or $N-R_{12}$;

n and m are each independently 0, 1 or 2, provided n + m = 1, 2, 3 or 4;

p and q are each independently 0, 1 or 2, provided p + q = 1, 2 or 3;

r is 1 or 2;

R_8, R_9, R_{10}, R_{11} and R_{12} are each independently a hydrogen or alkyl radical; or $-CR_8R_9-$ represents a -C(O)-;

B represents a radical of formula



wherein (a) R_{15} is a hydrogen or alkyl radical; and R_{17} is (1) an aryl, heteroaryl, $-NH-C(O)-R_{19}$, $-C(O)-NH-R_{19}$, $-NH-C(O)-NH-R_{19}$, $-O-C(O)-NH-R_{19}$, $-NH-C(O)-O-R_{19}$, $-S(O)_2-R_{19}$, $-NH-S(O)_2-R_{19}$, $-S(O)_2-NH-R_{19}$ or $-NH-S(O)_2-NH-R_{19}$ radical, or (2) an alkyl radical substituted by a radical of aryl, heteroaryl, $-NH-C(O)-R_{19}$, $-C(O)-NH-R_{19}$, $-NH-C(O)-NH-R_{19}$, $-O-C(O)-NH-R_{19}$, $-NH-C(O)-O-R_{19}$, $-S(O)_2-R_{19}$, $-NH-S(O)_2-R_{19}$, $-S(O)_2-NH-R_{19}$ or $-NH-S(O)_2-NH-R_{19}$; wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of R_2; or

(b) R_{17} is a hydrogen or alkyl radical; and R_{15} is (1) an aryl, heteroaryl, cycloalkyl, heterocyclyl, $-NH-C(O)-R_{19}$, $-C(O)-NH-R_{19}$, $-NH-C(O)-NH-R_{19}$, $-O-C(O)-NH-R_{19}$, $-NH-C(O)-O-R_{19}$, $-S(O)_2-R_{19}$, $-NH-S(O)_2-R_{19}$, $-S(O)_2-NH-R_{19}$ or $-NH-S(O)_2-NH-R_{19}$ radical, or (2) an alkyl radical substituted by a radical of aryl, heteroaryl, cycloalkyl, heterocyclyl, $-NH-C(O)-R_{19}$, $-C(O)-NH-R_{19}$, $-NH-C(O)-NH-R_{19}$, $-O-C(O)-NH-R_{19}$, $-NH-C(O)-O-R_{19}$, $-S(O)_2-$

R_{19}, $-NH-S(O)_2-R_{19}$, $-S(O)_2-NH-R_{19}$ or $-NH-S(O)_2-NH-R_{19}$ radical; wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2;

provided that when a nitrogen atom is attached to the carbon atom to which R_{15} is attached, then R_{15} is (1) an aryl, heteroaryl, cycloalkyl, heterocyclyl or $-C(O)-NH-R_{19}$ radical, or (2) an alkyl radical substituted by a radical of aryl, heteroaryl, cycloalkyl, heterocyclyl, $-NH-C(O)-R_{19}$, $-C(O)-NH-R_{19}$, $-NH-C(O)-NH-R_{19}$, $-O-C(O)-NH-R_{19}$, $-NH-C(O)-O-R_{19}$, $-S(O)_2-R_{19}$, $-NH-S(O)_2-R_{19}$, $-S(O)_2-NH-R_{19}$ or $-NH-S(O)_2-NH-R_{19}$;

wherein R_{19} is a alkyl, cycloalkyl, cycloalkyl-alkyl, aryl, aryl-alkyl, heteroaryl, heteroaryl-alkyl, heterocyclyl or heterocyclyl-alkyl, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2;

R_{16} and R_{18} are each independently a hydrogen or alkyl radical; and

E is a radical of carboxy, amido, tetrazolyl, $-C(O)-O-R_{20}$, $-C(O)-NH-R_{20}$, $-C(O)-NH-S(O)-R_{20}$, $-C(O)-NH-S(O)_2-R_{20}$ or $-C(O)-NH-C(O)-R_{20}$;

wherein R_{20} is an alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl radical or an alkyl radical substituted by 1-3 radicals of halo, hydroxy, carboxy, amino, cycloalkyl, aryl, heteroaryl or heterocyclyl, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2; and

provided that when U represents amidino, guanidino, -C(Q)-NH-R_1 or -NH-C(Q)-NH-R_1 radical, wherein Q represents NH, N-CN or N-alkyl, then at least one of g, h or j is 1.

2. The compound of Claim 1 or a pharmaceutically acceptable salt thereof, wherein

each Alk is independently a C_1-C_{12} alkyl radical;

U represents amidino, guanidino, -(G-(C_1-C_8 alkyl))$_k$-NH-R_1, -(G-(C_1-C_8 alkyl))$_k$-NH-C(Q)-R_1, -(G-(C_1-C_8 alkyl))$_k$-C(Q)-N(R)-R_1, -(G-(C_1-C_8 alkyl))$_k$-NH-C(Q)-N(R)-R_1, -(G-(C_1-C_8 alkyl))$_k$-NH-C(Q)-O-R_1 or -(G-(C_1-C_8 alkyl))$_k$-O-C(Q)-N(R)-R_1 radical; or U represents a hydroxy(C_1-C_{12} alkyl)-G- radical which is optionally substituted by a C_3-C_8 cycloalkyl, aryl, heteroaryl of 5-10 ring members or heterocyclyl of 5-8 ring members, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2;

Q represents O, S, NH, N-CN or N-(C_1-C_8 alkyl);

R is a radical of hydrogen or C_1-C_8 alkyl;

R_1 is a radical of C_1-C_8 alkyl, halo(C_1-C_8 alkyl) of 1-7 halo radicals, $R_{21}R_{22}$N-(C_1-C_8 alkyl), R_{21}O-(C_1-C_8 alkyl), R_{21}S-(C_1-C_8 alkyl), C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl(C_1-C_8 alkyl), aryl, aryl(C_1-C_8 alkyl), heteroaryl of 5-10 ring members, heteroaryl(C_1-C_8 alkyl) of 5-10 ring members, heterocyclyl of 5-8 ring members or heterocyclyl(C_1-C_8 alkyl) of 5-8 ring members, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2;

wherein R_{21} and R_{22} are each independently a radical of hydrogen, C_1-C_8 alkyl, halo(C_1-C_8 alkyl) of 1-7 halo radicals, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl(C_1-C_8 alkyl), aryl, aryl(C_1-C_8 alkyl), heteroaryl of 5-10 ring members, heteroaryl(C_1-C_8 alkyl) of 5-10 ring members, heterocyclyl of 5-8 ring members or heterocyclyl(C_1-C_8 alkyl) of 5-8 ring members, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2;

each R_2 is independently a halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 alkylthio, halo(C_1-C_4 alkyl) of 1-5 halo radicals, halo(C_1-C_4 alkoxy) of 1-5 halo radicals, hydroxy, carboxy, cyano, azido, amidino, guanidino, nitro, amino, C_1-C_8 alkylamino or di(C_1-C_8 alkyl)amino radical or two adjacent R_2 radicals on an aryl or heteroaryl radical represent a methylenedioxy, ethylenedioxy or propylenedioxy radical;

each R_3 is independently a hydrogen or C_1-C_6 alkyl radical;

each R_4 is independently a hydrogen, halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 alkylthio, halo(C_1-C_4 alkyl) of 1-5 halo radicals, halo(C_1-C_4 alkoxy) of 1-5 halo radicals, hydroxy, cyano, carboxy, -C(O)-O-R_{19}, -C(O)-R_{19}, -C(O)-NH-R_{19}, -C(O)-N(R_{19})$_2$, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkyl(C_1-C_4 alkyl), aryl, aryl(C_1-C_4 alkyl), heteroaryl of 5-10 ring members, heteroaryl(C_1-C_4 alkyl) of 5-10 ring members, heterocyclyl of 5-8 ring members or heterocyclyl(C_1-C_4 alkyl) of 5-8 ring members radical, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2; or two adjacent R_4 radicals taken together with the carbon atoms to which they are attached represent a fused-phenyl or fused-heteroaryl

of 5-6 ring members, wherein the phenyl and heteroaryl radicals are optionally substituted by 1-3 radicals of R_2;

R_5, R_6 and R_7 are each independently a hydrogen, halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 alkylthio, halo(C_1-C_4 alkyl) of 1-5 halo radicals, halo(C_1-C_4 alkoxy) of 1-5 halo radicals, hydroxy or cyano radical; or R_5 and R_6 or R_6 and R_7 taken together with the carbon atoms to which they are attached represent a fused-phenyl or fused-heteroaryl of 6 ring members, wherein the phenyl and heteroaryl radicals are optionally substituted by 1-3 radicals of R_2; or R_3 and R_6 taken together with the carbon atoms to which they are attached represent a fused-heteroaryl of 6 ring members optionally substituted by 1-3 radicals of R_2;

X_2 is C-H, C-(C_1-C_4 alkyl), a C_3-C_8 spirocycloalkyl or spiroheterocyclyl of 5-8 ring members radical; wherein the spirocycloalkyl and spiroheterocyclyl radicals are optionally substituted by an oxo or thiooxo radical and 1-2 radicals of C_1-C_6 alkyl, halo(C_1-C_4 alkyl) of 1-5 halo radicals, hydroxy, C_1-C_6 alkoxy or halo(C_1-C_4 alkoxy) of 1-5 halo radicals;

R_8, R_9, R_{10}, R_{11} and R_{12} are each independently a hydrogen or C_1-C_6 alkyl radical; or $-CR_8R_9-$ represents a -C(O)-;

B represents a radical of formula



wherein (a) R_{15} is a hydrogen or C_1-C_6 alkyl radical; and R_{17} is (1) an aryl, heteroaryl of 5-10 ring members, -

$NH-C(O)-R_{19}$, $-C(O)-NH-R_{19}$, $-NH-C(O)-NH-R_{19}$, $-O-C(O)-NH-R_{19}$, $-NH-C(O)-O-R_{19}$, $-S(O)_2-R_{19}$, $-NH-S(O)_2-R_{19}$, $-S(O)_2-NH-R_{19}$ or $-NH-S(O)_2-NH-R_{19}$ radical, or (2) an C_1-C_6 alkyl radical substituted by a radical of aryl, heteroaryl of 5-10 ring members, $-NH-C(O)-R_{19}$, $-C(O)-NH-R_{19}$, $-NH-C(O)-NH-R_{19}$, $-O-C(O)-NH-R_{19}$, $-NH-C(O)-O-R_{19}$, $-S(O)_2-R_{19}$, $-NH-S(O)_2-R_{19}$, $-S(O)_2-NH-R_{19}$ or $-NH-S(O)_2-NH-R_{19}$; wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of R_2; or

(b) R_{17} is a hydrogen or C_1-C_6 alkyl radical; and R_{15} is (1) an aryl, heteroaryl of 5-10 ring members, C_3-C_8 cycloalkyl, heterocyclyl of 5-8 ring members, $-NH-C(O)-R_{19}$, $-C(O)-NH-R_{19}$, $-NH-C(O)-NH-R_{19}$, $-O-C(O)-NH-R_{19}$, $-NH-C(O)-O-R_{19}$, $-S(O)_2-R_{19}$, $-NH-S(O)_2-R_{19}$, $-S(O)_2-NH-R_{19}$ or $-NH-S(O)_2-NH-R_{19}$ radical, or (2) an C_1-C_4 alkyl radical substituted by a radical of aryl, heteroaryl of 5-10 ring members, C_3-C_8 cycloalkyl, heterocyclyl of 5-8 ring members, $-NH-C(O)-R_{19}$, $-C(O)-NH-R_{19}$, $-NH-C(O)-NH-R_{19}$, $-O-C(O)-NH-R_{19}$, $-NH-C(O)-O-R_{19}$, $-S(O)_2-R_{19}$, $-NH-S(O)_2-R_{19}$, $-S(O)_2-NH-R_{19}$ or $-NH-S(O)_2-NH-R_{19}$ radical; wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2;

provided that when a nitrogen atom is attached to the carbon atom to which R_{15} is attached, then R_{15} is (1) an aryl, heteroaryl, cycloalkyl, heterocyclyl or $-C(O)-NH-R_{19}$ radical, or (2) an alkyl radical substituted by a radical of aryl, heteroaryl, cycloalkyl, heterocyclyl, $-NH-C(O)-R_{19}$, $-C(O)-NH-R_{19}$, $-NH-C(O)-NH-R_{19}$, $-O-C(O)-NH-R_{19}$, $-NH-C(O)-O-R_{19}$, $-S(O)_2-R_{19}$, $-NH-S(O)_2-R_{19}$, $-S(O)_2-NH-R_{19}$ or $-NH-S(O)_2-NH-R_{19}$;

wherein R_{19} is a C_1-C_6 alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl(C_1-C_6 alkyl), aryl, aryl(C_1-C_6 alkyl), heteroaryl of 5-10 ring members, heteroaryl(C_1-C_6 alkyl)

of 5-10 ring members, heterocyclyl of 5-8 ring members or heterocyclyl(C_1-C_6 alkyl) of 5-8 ring members, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2;

R_{16} and R_{18} are each independently a hydrogen or C_1-C_6 alkyl radical; and

R_{20} is a C_1-C_6 alkyl, C_3-C_8 cycloalkyl, aryl, heteroaryl of 5-10 ring members or heterocyclyl of 5-8 ring members radical or a C_1-C_6 alkyl radical substituted by 1-3 radicals of halo, hydroxy, carboxy, amino, C_3-C_8 cycloalkyl, aryl, heteroaryl of 5-10 ring members or heterocyclyl of 5-8 ring members, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2.

3. The compound of Claim 2 or a pharmaceutically acceptable salt thereof, wherein

each Alk is independently a C_1-C_8 alkyl radical;

V represents a radical of formula



,


,


,


,


,






A represents a radical of formula




; and

Y_1 is -C(O)- or -C(S)-.

4. The compound of Claim 3 or a pharmaceutically acceptable salt thereof, wherein

each Alk is independently a C_1-C_6 alkyl radical;

V represents a radical of formula




;

X_2 is C-H or C-(methyl) radical;

Y_1 is -C(O)-; and

R_8, R_9, R_{10}, R_{11} and R_{12} are each independently a hydrogen or methyl radical; or $-CR_8R_9-$ represents a -C(O)-.

5. The compound of Claim 4 or a pharmaceutically acceptable salt thereof, wherein

each Alk is independently a C_1-C_4 alkyl radical;

U represents amidino, guanidino, $-(G-(C_1-C_8\ alkyl))_k-NH-R_1$, $-(G-(C_1-C_8\ alkyl))_k-NH-C(Q)-R_1$, $-(G-(C_1-C_8\ alkyl))_k-C(Q)-N(R)-R_1$, $-(G-(C_1-C_8\ alkyl))_k-NH-C(Q)-N(R)-R_1$ or $-(G-(C_1-C_8\ alkyl))_k-NH-C(Q)-O-R_1$ radical;

G represents a bond, O or NH;

Q represents O, S, NH, N-CN or N-(C_1-C_4 alkyl);

R is a radical of hydrogen or C_1-C_4 alkyl;

R_1 is a radical of C_1-C_6 alkyl, halo(C_1-C_6 alkyl) of 1-5 halo radicals, $R_{21}R_{22}N-(C_1-C_6\ alkyl)$, $R_{21}O-(C_1-C_6\ alkyl)$, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl(C_1-C_6 alkyl), aryl, aryl(C_1-C_6 alkyl), heteroaryl of 5-10 ring members, heteroaryl(C_1-C_6 alkyl) of 5-10 ring members, heterocyclyl of 5-8 ring members or heterocyclyl(C_1-C_6 alkyl) of 5-8 ring members, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2;

R_{21} and R_{22} are each independently a radical of hydrogen, C_1-C_8 alkyl, aryl, aryl(C_1-C_4 alkyl), heteroaryl of 5-10 ring members or heteroaryl(C_1-C_4 alkyl) of 5-10 ring

members, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of R_2;

each R_2 is independently a halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, halo(C_1-C_2 alkyl) of 1-5 halo radicals, halo(C_1-C_2 alkoxy) of 1-5 halo radicals, hydroxy, carboxy, cyano, azido, amidino, guanidino, nitro, amino, C_1-C_4 alkylamino or di(C_1-C_4 alkyl)amino radical or two adjacent R_2 radicals on an aryl or heteroaryl radical represent a methylenedioxy, ethylenedioxy or propylenedioxy radical;

each W_6 is C-H;

each R_4 is independently a hydrogen, halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, halo(C_1-C_2 alkyl) of 1-5 halo radicals, halo(C_1-C_2 alkoxy) of 1-5 halo radicals, hydroxy, cyano, carboxy, -C(O)-O-R_{19}, -C(O)-R_{19}, -C(O)-NH-R_{19}, -C(O)-N(R_{19})$_2$, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkyl(C_1-C_4 alkyl), aryl, aryl(C_1-C_4 alkyl), heteroaryl of 5-10 ring members, heteroaryl(C_1-C_4 alkyl) of 5-10 ring members, heterocyclyl of 5-8 ring members or heterocyclyl(C_1-C_4 alkyl) of 5-8 ring members radical, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2; and

R_{20} is a C_1-C_4 alkyl, aryl or heteroaryl of 5-10 ring members or a C_1-C_4 alkyl radical substituted by 1-3 radicals of halo, hydroxy, carboxy, amino, aryl, heteroaryl of 5-10 ring members or heterocyclyl of 5-8 ring members, wherein the aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2.

6. The compound of Claim 5 or a pharmaceutically acceptable salt thereof, wherein

U represents amidino, guanidino, $-(G-(C_1-C_8\ alkyl))_k-NH-R_1$, $-NH-C(Q)-R_1$, $-(G-(C_1-C_8\ alkyl))_k-C(Q)-N(R)-R_1$, $-NH-C(Q)-N(R)-R_1$ or $-NH-C(Q)-O-R_1$ radical;

Q represents O or NH;

R is a radical of hydrogen or C_1-C_2 alkyl;

R_1 is a radical of C_1-C_6 alkyl, halo(C_1-C_6 alkyl) of 1-5 halo radicals, $R_{21}R_{22}N-(C_1-C_4\ alkyl)$, $R_{21}O-(C_1-C_4\ alkyl)$, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl(C_1-C_4 alkyl), aryl, aryl(C_1-C_4 alkyl), heteroaryl of 5-10 ring members, heteroaryl(C_1-C_4 alkyl) of 5-10 ring members, heterocyclyl of 5-8 ring members or heterocyclyl(C_1-C_4 alkyl) of 5-8 ring members, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2;

R_{21} and R_{22} are each independently a radical of hydrogen, C_1-C_6 alkyl, aryl or heteroaryl of 5-10 ring members, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of R_2;

each R_2 is independently a halo, C_1-C_2 alkyl, C_1-C_2 alkoxy, C_1-C_2 alkylthio, CF_3-, CF_3O-, hydroxy, carboxy, cyano, azido, amidino, guanidino, nitro, amino, C_1-C_2 alkylamino or di(C_1-C_2 alkyl)amino radical or two adjacent R_2 radicals on an aryl or heteroaryl radical represent a methylenedioxy, ethylenedioxy or propylenedioxy radical;

each W_2, W_3, W_4 and W_5 are independently $C-R_4$;

each R_4 is independently a hydrogen, halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkylthio, halo(C_1-C_2 alkyl) of 1-5 halo radicals, halo(C_1-C_2 alkoxy) of 1-5 halo radicals, hydroxy or cyano radical;

A represents a radical of formula



or



;

(a) R_{15} is a hydrogen or C_1-C_2 alkyl radical; and R_{17} is -NH-C(O)-R_{19}, -NH-C(O)-NH-R_{19}, -NH-C(O)-O-R_{19}, -NH-S(O)$_2$-R_{19} or -NH-S(O)$_2$-NH-R_{19} radical; or (b) R_{17} is a hydrogen or C_1-C_2 alkyl radical; and R_{15} is (1) an aryl, heteroaryl of 5-10 ring members, C_3-C_8 cycloalkyl or heterocyclyl of 5-8 ring members radical, or (2) an C_1-C_2 alkyl radical substituted by a radical of aryl, heteroaryl of 5-10 ring members, C_3-C_8 cycloalkyl or heterocyclyl of 5-8 ring members radical; wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl radicals are optionally substituted by 1-3 radicals of R_2;

R_{19} is a C_1-C_4 alkyl, aryl, aryl(C_1-C_4 alkyl), heteroaryl of 5-10 ring members or heteroaryl(C_1-C_4 alkyl) of 5-10 ring members, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of R_2;

R_{16} and R_{18} are each independently a hydrogen or C_1-C_4 alkyl radical;

E is a radical of carboxy, amido, tetrazolyl or -C(O)-O-R_{20}; and

R_{20} is a C_1-C_2 alkyl, aryl or heteroaryl of 5-10 ring members or a C_1-C_2 alkyl radical substituted by 1-3 radicals of halo, hydroxy, carboxy, aryl or heteroaryl of 5-10 ring members, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of R_2.

7. The compound of Claim 6 or a pharmaceutically acceptable salt thereof, wherein

Alk is independently a C_1-C_2 alkyl radical;

G represents a bond or NH;

R_{21} and R_{22} are each independently a radical of hydrogen, C_1-C_6 alkyl or aryl, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of R_2;

each R_4 is independently a hydrogen, halo, C_1-C_2 alkyl, C_1-C_2 alkoxy, C_1-C_2 alkylthio, CF_3-, CF_3O-, hydroxy or cyano radical;

A represents a radical of formula



;

(a) R_{15} is a hydrogen or C_1-C_2 alkyl radical; and R_{17} is -NH-C(O)-O-R_{19} or -NH-S(O)$_2$-R_{19} radical; or (b) R_{17} is a hydrogen or C_1-C_2 alkyl radical; and R_{15} is (1) an aryl or heteroaryl of 5-10 ring members, or (2) an C_1-C_2

alkyl radical substituted by a radical of aryl or heteroaryl of 5-10 ring members; wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of R_2;

R_{19} is a C_1-C_4 alkyl, aryl or aryl(C_1-C_4 alkyl), wherein the aryl radicals are optionally substituted by 1-3 radicals of R_2;

R_{16} and R_{18} are each independently a hydrogen or C_1-C_2 alkyl radical;

E is a radical of carboxy or -C(O)-O-R_{20}; and

R_{20} is a C_1-C_2 alkyl, aryl or aryl(C_1-C_2 alkyl) radical, wherein the aryl radicals are optionally substituted by 1-3 radicals of R_2.

8. A pharmaceutical composition comprising a compound according to any of Claims 1 to 7 and a pharmaceutically acceptable carrier.

9. A method for the treatment of a disease or disorder modulated by an integrin receptor comprising administering an effective amount of a compound according to any of Claims 1 to 7.

10. The method of Claim 9 wherein the integrin receptor is vitronectin receptor $\alpha_v\beta_3$, $\alpha_v\beta_5$ or $\alpha_v\beta_6$.

11. A method for the treatment of a disease or disorder modulated by an integrin receptor comprising administering an effective amount of a composition of Claim 8.

12. The method of Claim 11 wherein the an integrin receptor is vitronectin receptor $\alpha_v\beta_3$, $\alpha_v\beta_5$ or $\alpha_v\beta_6$.

13. A method of antagonizing an integrin receptor comprising administering an effective amount of a compound according to any of Claims 1 to 7.

14. The method of Claim 13 wherein the an integrin receptor is vitronectin receptor $\alpha_v\beta_3$, $\alpha_v\beta_5$ or $\alpha_v\beta_6$.

15. A method of antagonizing an integrin receptor comprising administering an effective amount of a composition of Claim 8.

16. The method of Claim 15 wherein the an integrin receptor is vitronectin receptor $\alpha_v\beta_3$, $\alpha_v\beta_5$ or $\alpha_v\beta_6$.

17. A method for the treatment of atherosclerosis, restenosis, inflammation, wound healing, cancer, metastasis, bone resorption related diseases, diabetic retinopathy, macular degeneration, angiogenesis or viral infections comprising administering an effective amount of a compound according to any of Claims 1 to 7.

18. A method for the treatment of atherosclerosis, restenosis, inflammation, wound healing, cancer, metastasis, bone resorption related diseases, diabetic retinopathy, macular degeneration, angiogenesis or viral infections comprising administering an effective amount of a composition of Claim 8.